Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 25 of 65 · 3104 articles
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Biomarkers. The original article is from Biochemia medica.
Older adults (≥60) with IBD are an increasing population worldwide, and IBD-related anemia is rising—this affects screening needs, healthcare planning, and resource allocation. The findings point to widening...
Patients who present with new radiologic terminal ileitis sometimes develop Crohn’s disease. Identifying simple blood and imaging markers that predict who is at higher risk could help prioritize follow-up or specialist...
The study proposes a new redox-regulatory pathway (Grx1–STAT6) that helps M2 macrophages drive tissue repair and colitis recovery in preclinical models, pointing to a possible new therapeutic target to promote...
This study suggests that a confirmed Campylobacter stool infection in people with IBD was followed by higher rates of flare and need for treatment escalation within 12 months, so infected patients might need closer...
A validated Spanish IBD-Disk gives Spanish-speaking patients and clinicians a brief, validated tool to measure disability and global health in IBD, supporting consistent monitoring and research across Spanish-speaking...
Patients with moderate-to-severe Crohn's disease who do not respond to anti-TNF drugs have limited options. This study suggests combining ustekinumab with upadacitinib may improve endoscopic healing versus either drug...
This trial describes a large Phase 3 extension study collecting long-term safety and tolerability data for tulisokibart (MK-7240), an investigational TL1A-targeting antibody for Crohn’s disease and ulcerative colitis....
Psychological distress is common in IBD and often goes unaddressed; a peer-led virtual program could expand access to emotional support and inform larger trials if found feasible and acceptable.
This trial tests an oral live biotherapeutic (MH002) aimed at restoring a healthier gut microbiome in people with mild-to-moderate ulcerative colitis. If effective and safe, it would offer a non-immunosuppressive,...
Thalidomide can help treat refractory pediatric IBD but causes peripheral neuropathy. Knowing a cumulative-dose threshold linked to neuropathy could help clinicians balance benefit and neurotoxicity risk.
Differences in urbanisation and socioeconomic development may help explain rising IBD rates in newly industrialised regions and point to where earlier diagnosis and healthcare planning might be needed. The association...
The findings highlight that older adults are less likely to be prescribed advanced IBD therapies, which could reflect prescribing patterns, comorbidities, insurance factors, or access issues relevant to treatment...
Identifies a molecule (CCL3) linked to more severe inflammation in IBD tissues, which could help researchers develop new biomarkers or treatments targeting immune-cell recruitment and polarization.
The study proposes a new oral nanoparticle that targets neutrophil-driven oxidative stress linked to mucosal barrier damage, a mechanism relevant to IBD pathology. If translatable, this approach could add a new modality...
The study describes a targeted oral delivery system for 5-ASA that aims to concentrate drug release in the colon and also leverage inulin’s prebiotic/immunomodulatory properties—potentially improving effectiveness and...
Depression is common in Crohn’s disease and appears linked to immune and microbial signals from the gut. Understanding gut–brain mechanisms could improve how mood symptoms are detected and treated in people with IBD.
Targeted oral delivery of melatonin could reduce inflammation and help repair the intestinal barrier in UC by acting on macrophages and epithelial cells. If translated to humans, this approach might offer a locally...
AMPs are central to gut immune balance and are being explored as new therapies for IBD and related gut diseases. For people with Crohn’s or IBD, understanding AMPs helps explain research directions aimed at restoring...
The study connects a bothersome UC symptom (bowel urgency) to intestinal ultrasound signs of transmural inflammation, suggesting ultrasound might help explain and track symptom-related inflammation without relying solely...
SRCEUS may offer higher-resolution, noninvasive assessment of intestinal microvascular changes that correspond to Crohn disease activity, which could improve monitoring and reduce reliance on invasive tests.
Identifies a stromal-cell subset marked by TIMP1 that may play a role in UC pathogenesis and might serve as a candidate biomarker or therapeutic target; useful for researchers and clinicians following emerging...
Better automated scoring tools for endoscopic images could reduce variability between human reviewers and help standardize assessments of ulcerative colitis severity used for treatment decisions and monitoring.
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical...
The study reports anti-inflammatory and antioxidant effects of a new andrographolide formulation in a macrophage model relevant to ulcerative colitis, highlighting a potential early-stage therapeutic lead that may...
People with IBD are often interested in how dietary fibers and the microbiome might influence inflammation.
Clinical trials test new treatments that could become options for people with moderate to severe Crohn’s disease. This sponsor-supported notice also highlights the need for broader representation in research, which...
Stress and psychological distress are common in people with IBD and may influence symptoms and inflammation. This trial tests whether an 8‑week MBSR program can improve psychological wellbeing and whether those benefits...
This trial tests standardized encapsulated fecal microbiota products as a microbiome-directed therapy for active Crohn’s disease, focusing on whether donor microbes engraft in the ileum and colon and whether that relates...
Macrophage pyroptosis is increasingly implicated in driving intestinal inflammation and barrier damage in IBD, so understanding it could point to new treatment targets. Patients and clinicians may find this research...
Juvenile colorectal polyps in children show strong type 2 inflammatory and epithelial-remodeling programs that could explain links with allergic sensitization and suggest biomarkers and pathways relevant to mucosal...
This study models comparative cost-effectiveness across many advanced therapy sequences for moderate–severe ulcerative colitis in Japan; its findings could influence how health systems and clinicians consider first- and...
This review highlights shared biomarkers and mechanisms between early Crohn's disease and post-operative recurrence, which could improve prediction and lead to preventive strategies for recurrence after surgery.
The paper presents a proof-of-concept immune-based assay to match donors and recipients for FMT in IBD, which could help explain variable FMT outcomes and improve donor selection if validated.
The study identifies a β-glucan → IL-33 → active eosinophil pathway that reduced colitis in a mouse model, suggesting a novel immunomodulatory mechanism that could inform future IBD research.
The study suggests a hidden, early molecular defect that leaves intestinal cells primed to die even during clinical remission, which could help explain why flares recur. Measuring these molecular signals might eventually...
Dysplasia detection during colonoscopy is central to preventing colorectal cancer in people with IBD. AI tools could help, but current models often fail in inflamed or IBD-specific settings, so this review outlines...
Intestinal barrier dysfunction is a likely driver of inflammation and flares in ulcerative colitis, so therapies that restore barrier integrity could help reduce disease activity and recurrence. This review highlights...
The study suggests shared MHC/HLA genetic variants link ulcerative colitis and gastric cancer risk in East Asians, highlighting potential common immune-related susceptibility that could inform research on disease...
Older adults with IBD are under-represented in trials, so age-specific benefits and harms of newer oral drugs (JAK inhibitors and S1P modulators) are uncertain. Clinicians and patients may need to weigh efficacy against...
If pre‑treatment biopsy features predict response to ustekinumab, clinicians might better select which UC patients are likely to benefit, potentially avoiding ineffective therapy for some and speeding effective treatment...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Biomedical Signal...
The study provides real-world data on ozanimod effectiveness, safety, and how prior biologic exposure (notably vedolizumab) may affect treatment persistence—information relevant for treatment planning in UC.
This mouse study connects fat malabsorption, increased gut permeability, microbiome shifts, and reduced oxalate transport to higher oxalate absorption and kidney injury—mechanisms relevant to enteric hyperoxaluria seen...
Researchers are exploring ways to improve cell therapies for IBD by making therapeutic cells produce anti-inflammatory molecules like IL-10. If scalable and safe, non-viral engineering of MSCs could lead to...
New colon-targeted formulations aim to concentrate treatment where inflammation is in ulcerative colitis, which could increase benefit and reduce systemic side effects. Formulation research like this is an early step...
The work links climate and sociodemographic context to IBD burden in tropical regions, which can influence diagnostic recognition, resource needs, and research priorities for communities where IBD is rising.
People with IBD commonly experience anxiety, depression, and other neurological symptoms. Understanding gut–brain axis mechanisms may help explain these comorbidities and point to future treatments.
